Xigris "Dear Doctor" Letter Follows Termination Of Pediatric Sepsis Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly says a data monitoring committee determined that Xigris was "highly unlikely to show improvement over placebo" in the study's primary endpoint – composite time to complete organ failure resolution.
You may also be interested in...
Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future
Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?
Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future
Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?
The Long Goodbye: Lilly Finally Kicks Troubled Sepsis Drug Xigris To The Curb
Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.